Info@ThinkPinkRocks.com

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T.

Continue Reading:
Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Share

Leave a Reply